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Background: Mutations in CDH23 are responsible for Usher syndrome 1D and recessive non-syndromic hearing loss.
In this study, we revealed the prevalence of CDH23 mutations among patients with specific clinical characteristics.
Methods: After excluding patients with GJB2 mutations and mitochondrial m.1555A > G and m.3243A > G mutations,
subjects for CDH23 mutation analysis were selected according to the following criteria: 1) Sporadic or recessively
inherited hearing loss 2) bilateral non-syndromic congenital hearing loss, 3) no cochlear malformation, 4) a poorer
hearing level at high frequencies than at low frequencies, and 5) severe or profound hearing loss at higher frequencies.
Results: Seventy-two subjects were selected from 621 consecutive probands who did not have environmental causes
for their hearing loss. After direct sequencing, 13 of the 72 probands (18.1%) had homozygous or compound
heterozygous CDH23 mutations. In total, we identified 16 CDH23 mutations, including five novel mutations. The
16 mutations included 12 missense, two frameshift, and two splice-site mutations.
Conclusions: These results revealed that CDH23 mutations are highly prevalent in patients with congenital
high-frequency sporadic or recessively inherited hearing loss and that the mutation spectrum was diverse, indicating
that patients with these clinical features merit genetic analysis.
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CDH23, located on chromosome 10, contains 70 exons
and encodes a predicted 3354 amino acid protein. The
untranslated region is followed by 27 extracellular cad-
herin repeat domains (exons 2–64), a single-pass trans-
membrane domain (exon 65), and a cytoplasmic domain
(exons 66–70). Among the 113 human cadherin super-
family members, CDH23 is one of 11 that are solely
responsible for hereditary diseases [1]. CDH23 is
expressed in the outer and inner hair cells. The stereo-
ciliary expression of CDH23 in inner ear hair cells ex-
hibits two patterns. One is transient expression during* Correspondence: matsunagatatsuo@kankakuki.go.jp
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© 2015 Mizutari et al.the development of hair bundles with procadherin 15
(PCDH15) and CDH23 forming side links and kinocili-
ary links at their N-termini [2]. The second pattern is
stable expression in tip links at the top of stereocilia
from the developmental stage onwards until ear matur-
ation. CDH23 homodimers interact in trans with
PCDH15 homodimers to form filaments, and they play a
key role in the mechanoelectrical transduction channel
at the top of the lower stereocilia [3-5].
Mutations in CDH23 are responsible for both Usher
syndrome 1D (USH1D: OMIM #601067) [6-9] and auto-
somal recessive non-syndromic hearing loss (DFNB12:
OMIM #601386) [10-12]. Individuals with USH1D usu-
ally carry a truncated CDH23 protein because of non-
sense, frameshift, or splice-site mutations, whereas those
with DFNB12 usually carry missense mutations in any
domain [7,10,13]. The mutation spectrums differ region-
ally, with the Japanese population having a unique
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that 3.7% of recessive inherited hearing loss cases in the
Japanese population involve homozygous or heterozy-
gous CDH23 mutations [12].
In this study, we analyzed CDH23 in a Japanese popu-
lation that was selected on the basis of DFNB12 and
USH1D clinical features [12,14-16] after excluding patients
with GJB2 mutations and mitochondrial m.1555A >G and
m.3243A >G mutations. We identified an extremely high
prevalence of CDH23 mutations in this population, and
our findings expanded the CDH23 mutation spectrum,
including five novel mutations.
Methods
All participating subjects, or their parents if the subjects
were less than 20 years old, provided informed consent.
The project was approved by the institutional review
board of each institute. The patients were collected from
the 11 institutes listed below: National Tokyo Medical
Center, Chiba Children’s Hospital, National Mie Hospital,
National Center for Child Health and Development, Hyogo
Prefectural Kobe Children’s Hospital, Keio University
School of Medicine, National Hospital Organization
Kanazawa Medical Center, Kanagawa Children’s Medical
Center, National Hospital Organization Sendai Medical
Center, Kanto Rosai Hospital, and Hiroshima Prefectural
Hospital. All investigations were conducted according to
the principles expressed in the Declaration of Helsinki.
For the analysis of CDH23 mutations, we selected
subjects who did not have hearing loss owing to envir-
onmental causes and who had participated in a genetic
study at our institutes, with each subject meeting the fol-
lowing criteria: 1) sporadic or recessively inherited hear-
ing loss; 2) bilateral non-syndromic congenital hearing
loss; 3) a lack of cochlear malformations among those
who underwent a computed tomography scan and/or
magnetic resonance imaging; 4) a poorer hearing level at
high frequencies (e.g., 2 kHz, 4 kHz) than at low fre-
quencies (e.g., 250 kHz, 500 Hz); and 5) severe or pro-
found hearing loss over 70 dB at frequencies exceeding
2 kHz. These clinical features were based on the re-
ported phenotypes of DFNB12 and USH1D [12,14-16].
Before patient selection for CDH23 mutation analysis,
genetic analyses for GJB2 and mitochondrial m.1555A >G
and m.3243A >G mutations were conducted in all pa-
tients, according to published methods [17,18]. Among
621 probands who participated in a genetic study at our in-
stitutes from November 2008 to June 2012 (the first sub-
ject group), 72 subjects were selected for CDH23 mutation
analysis based on these criteria.
For CDH23 analysis, DNA was extracted from peripheral
blood using standard procedures. We PCR-amplified all
CDH23 exons using the primers listed in Additional file 1:
Table S1. The PCR products were purified and subjectedto sequencing using the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, CA, USA). SeqScape
2.6 software (Applied Biosystems) was used to analyze data
against an NCBI human primary reference sequence
(GRCh37.p13). Before SeqScape 2.6 analysis, all known
CDH23 mutations within 69 coding regions and flanking
10-bp sequences of transcript variant 1 archived in the
BIOBASE HGMD database (last visited on October 2014;
BIOBASE, MA, USA) were entered into the SeqScape pro-
ject files to enable detection of novel variants. Descriptions
of DNA and amino acid positions in the literature
[6-10,12,14,19] and the HGMD database were reassigned
through original test programs to present the information
in a consistent format. Prediction of the effect of missense
variants on CDH23 protein function was performed using
Polymorphism Phenotyping [PolyPhen2 [20] and Protein
Variation Effect Analyzer (PROVEAN v1.1.3.) [21].
Frameshift (splice site within ± 2) and nonsense muta-
tions were categorized as pathogenic. The pathogenicity
of splice site alterations larger than ± 2 was predicted by
NNSPLICE 0.9 version [22]. Novel missense variants
were defined as pathogenic if they were 1) non-
synonymous; 2) exhibited a low carrier rate (<1%) in 96
normal in-house control Japanese subjects and in public
databases [(dbSNP135 [23], 1000GENOME [24], and
NHLBI Exome Variant Server [25]]; 3) exhibited high
amino acid conservation among 12 primate, 45 mammal,
and 43 vertebrate species using UCSC Conservation
[26]; 4) demonstrated consistency with phenotypes in
family members; and 5) were detected in patients with
hearing loss identified as heterozygous in association
with another previously reported or determined hetero-
zygous mutation. Variants who failed to meet criteria
1–4 were defined as non-pathogenic. Those who met
criteria 1–4 but failed to fulfill criterion 5 were considered
to have uncertain pathogenicity. For the purpose of this
study, frameshift, splice site, and nonsense mutations were
categorized as “truncating” mutations, and missense and
in-frame insertion or deletion mutations were considered
“non-truncating” mutations.
In addition, we further examined CDH23 mutations
retrospectively in subjects who participated in a genetic
study at our institutes from April 2001 to October 2008
(the second subject group). For this analysis, we selected
subjects who had obvious progressive hearing loss as
determined by repeated audiometry, profound hearing
loss over 80 dB at frequencies above 2 kHz, as well as
fulfilling the five aforementioned criteria for the first
subject group. For these subjects, we additionally per-
formed Sanger sequencing for CDH23 mutations.
Results
In the first subject group, we analyzed a total of 621 pro-
bands, and 492 underwent clinical selection for CDH23
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tions and mitochondrial deafness. Figure 1 presents the
study procedure together with the selection process for
the primary screening. Using this procedure, 72 subjects
were selected for CDH23 mutation analysis (14.6% of
the selected individuals). Homozygous or compound
heterozygous CDH23 mutations were identified in 13
subjects (18.1% of tested subjects), and nine subjects had
heterozygous mutations (12.5% of tested subjects).
In the second subject group, 546 probands participated
in the genetic study. After retrospective selection using
the more stringent criteria, 15 subjects were selected.
After direct sequencing for CDH23 mutations, three
subjects were identified with homozygous or compound
heterozygous pathogenic CDH23 mutations (20.0% of
tested subjects), and three subjects were shown to have
heterozygous mutations (20.0% of tested subjects).
A total of 16 pathogenic CDH23 mutations were found
in 56 subjects from 28 families. Homozygous or com-
pound heterozygous pathogenic mutations were found
in 21 subjects, which included 16 probands. Heterozy-
gous mutations were found in 12 probands. CDH23
mutations included 11 previously reported mutations
[p.P240L, p.P346S, p.E956K, p.D1626A, p.Q1716P,
p.R2029W, p.R1417W, p.E2438K, p.L2473P, p.R2489H,
and c.6712 + 1G >A [7,12,14,27], as well as four novel mu-
tations (Table 1). Twelve of the mutations were missense,
one was a frameshift and three were splice-site mutations.
Fifteen variants were considered to have uncertain patho-
genicity (Table 1). These include five variants previously
reported as uncertain [12,14,28,29], as well as 10 novel
variants. We also found 49 non-pathogenic CDH23
variants, including 12 new variants (Additional file 2:Figure 1 Flow chart of the selection and exclusion processes and
the number of subjects at each point.Table S2). All the variants reported in this study were reg-
istered in the LOVD-CDH23 database [30].
Overlapping audiograms of all 21 subjects with bialle-
lic CDH23 mutations are shown in Figure 2. The ages of
these patients ranged from 0 to 25 years (median:
5 years). The average hearing level was 90.1 ± 12.3 (SD)
dB. The average hearing level at 250 and 500 Hz was
70.5 ± 22.7 dB, whereas that at 2000 and 4000 Hz was
101.9 ± 7.8 dB. In addition, 10 of 21 subjects displayed
obvious progressive hearing loss, as assessed by compar-
ing audiograms obtained at younger ages. At the time of
this study, no subjects were diagnosed with Usher syn-
drome, which, in addition to hearing loss, is associated
with vestibular dysfunction and visual impairment due
to retinitis pigmentosa. Information for vision, fundos-
copy, and motor milestones in 21 subjects with biallelic
CDH23 mutations is shown in Table 2.
The most frequent mutation in this study was
p.P240L, which is consistent with previous reports of the
Japanese population [12,14]. The overlapping audio-
grams illustrated that a high proportion of subjects
homozygous for the p.P240L mutation had more severe
low frequency hearing loss compared with subjects
with non-p.P240L homozygous mutations, indicating
a genotype-phenotype correlation (Figure 3).
Five of 21 subjects with biallelic CDH23 mutations
had an allele with a truncating mutation, such as a
frameshift or splice-site mutation, in association with a
missense mutation on the other allele. The other 16 sub-
jects had biallelic missense mutations. The overlapping
audiograms of these subjects revealed no significant dif-
ferences between the subjects with truncating mutations
associated with missense mutations and those with bial-
lelic missense mutations (Figure 4). The average hearing
level of the subjects with an allele featuring truncating
mutations associated with missense mutations was
90.3 ± 17.2 dB, whereas that of patients with biallelic
missense mutations was 90.0 ± 10.2 dB. Because the num-
ber of subjects with truncating mutations was small, this
result needs to be confirmed in a future study.
Discussion
The present results revealed an extremely high preva-
lence of CDH23 mutations among patients with con-
genital sporadic or recessively inherited high-frequency
hearing loss. Among 72 probands presenting with our
defined set of clinical features, 13 subjects (18.1%) exhib-
ited homozygous or compound heterozygous CDH23
mutations. Previously, a large cohort study of a Japanese
population (n = 1396) using two-step screening revealed
that the frequency of biallelic CDH23 mutations was
only 1.6% in patients with hearing loss [14]. The higher
prevalence of CDH23 mutations in the present study
can be explained by subject selection criteria; these
Table 1 Possible pathologic and uncertain variants found in this study
Number in probands (in 346 allele)
Types of variants Location Amino acid change Nucleotide change Genomic position(Chr10) Domain Evolutionary conservation* Homozygote Compound heterozygote
Missense Exon 7 p.P240L c.719C > T 73330641 EC3 11/11, 44/44, 40/40 4 7
Exon 11 p.P346S c.1036C > T 73377052 - 12/12, 42/42, 41/41 0 1
Exon 16 p.G539D c.1616G > A 73437314 EC5 12/12, 43/43, 42/42 0 1
Exon 18 p.D645G c.1934A > G 73442277 EC6 12/12, 45/45, 42/42 0 1
Exon 25 p.E956K c.2866G > A 73464800 EC9 12/12, 45/45, 42/42 0 4
Exon 35 p.R1417W c.4249C > T 73498294 EC13 12/12, 32/44, 0/40 0 0
Exon 39 p.D1626A c.4877A > C 73537468 EC15 12/12, 45/45, 41/42 0 1
Exon 39 p.Q1716P c.5147A > C 73538025 EC16 12/12, 45/45, 40/41 0 2
Exon 46 p.R2029W c.6085C > T 73550924 EC19 12/12, 45/45, 39/40 0 2
Exon 52 p.E2438K c.7312G > A 73559336 EC23 12/12, 43/44, 15/41 0 2
Exon 53 p.L2473P c.7418 T > C 73560448 EC23 11/11, 45/45, 36/36 0 0
Exon 53 p.R2489H c.7466G > A 73560496 EC23 12/12, 45/45, 36/36 0 0
Frameshift Exon 48 p.L2223Wfs c.6667del C 73553352 - - 0 1
Exon 63 p.N3044Tfs c.9129 del G 73571123 - - 0 1
Putative spice site IVS11 - c.1135-1G > T 73403617 - 12/12, 41/41, 4/4 0 0
IVS48 - c.6712 + 1G > A 73553398 - 712/12, 44/44, 41/41 0 1
Uncertain pathogenicity variants
Missense Exon 13 p.V424M c.1270G > A 73405717 EC4 12/12, 44/45, 0/36 0 0
Exon 13 p.D428N c.1282G > A 73405729 EC4 12/12, 39/45, 0/36 0 0
Exon 35 p.I1406V c.4216A > G 73498261 EC13 12/12, 43/44, 40/40. 0 0
Exon 38 p.G1583S c.4747G > A 73501580 EC15 12/12, 44/44, 41/43 0 0
Exon 40 p.V1711I c.5131G > A 73538009 EC16 12/12, 29/45, 11/41 0 0
Exon 42 p.G1799W c.5395G > T 73544070 EC17 11/11, 45/45, 42/43 0 0
Exon 44 p.V1908I c.5722G > A 73545397 EC9 11/12, 28/45, 33/41 0 0
Exon 48 p.D2202E c.6606C > A 73553291 EC21 12/12, 45/45, 41/42 0 0
Exon 48 p.Q2227P c.6680A > C 73553365 EC21 12/12, 44/44, 23/41 0 0
Exon 57 p.D2717N c.8149G > A 73566009 EC25 12/12, 45/45, 42/42 0 0
Exon 61 p.G2912S c.8734G > A 73569588 EC27 11/11, 45/45, 42/42 0 0
Exon 70 p.V3343M c.10027G > A 73574997 - 12/12, 45/45, 16/37 0 0
Putative splice site IVS2 - c.68-3C > T 73206072 - 12/12, 40/44, 18/19 0 0
IVS7 - c.625-5C > T 73330542 - 11/12, 41/44, 0/40 0 0














Number in probands (in 346 allele)
Types of variants Heterozygote Allele frequency in normal controls Allele frequency in ESP6500 dbSNP135 PolyPhen2 score PROVEAN score Novel or Known Reference
Missense 6 0/192 0 rs121908354 0.999 −3.051 Known [12]
0 0/192 0 None 0.989 −5.768 Known [27]
0 0/190 0 None 0.092 −4.272 Novel
0 0/192 0 None 1.000 −5.596 Novel
0 0/192 0 None 0.999 −2.939 Known [14]
1 0/192 0 None 0.453 −1.346 Known [12]
0 0/192 0 None 0.952 −5.3 Known [14]
0 0/192 0 None 0.972 −2.68 Known [12]
2 0/192 0 None 0.999 −4.659 Known [12]
0 0/192 0 None 0.314 −0.383 Known [14]
1 0/192 0 None 0.998 −5.603 Known [12]
1 0/192 0 rs141986620 0.459 −1.219 Known [12]
Frameshift 0 0/192 0 None - - Novel
0 0/190 0 None - - Novel
Putative spice site 1 0/192 0 None - - Novel
0 0/192 0 None - - Known [11]
Uncertain pathogenicity variants
Missense 1 0/190 0 rs2305207 0.557 −0.572 Novel
4** 0/190 0 rs188376296 0.103 −0.045 Novel
1 1/189 0 rs192459984 0.029 −0.304 Novel
1 0/192 0 None 1.000 −4.967 Novel
1 1/192 1/12645 rs181611778 0.998 −0.599 Known [12]
1** 0/192 0 None 0.998 −6.237 Novel
1 0/192 0 None 0.005 0.125 Known [14]
1** 0/190 0 None 1.000 −3.068 Known [28]
1 0/192 0 None 0.729 −0.775 Known [29]
1** 0/190 0 None 0.999 −1.909 Novel
1 0/192 0 None 0.774 −2.221 Known [14]
1** 0/188 0 None 0.670 −0.427 Novel
Putative splice site 1 0/188 0 rs142456469 - - Novel
1 0/192 0 None - - Novel
1 0/192 0 None - - Novel
*Evolutionary conservation showed up to 12 primates, 45 mammals, and 43 vertebrates, respectively.














Figure 2 Overlapping audiograms of subjects with hearing loss caused
by CDH23 mutations. Overlapping audiograms of the better-hearing
ear of 20 subjects with homozygous or compound heterozygous
CDH23 mutations.
Table 2 Clinical and genetic data in the patients with biallelic
Case ID*1 Age at the latestexamination Genotypes*2
1 25y11m p.P240L / p.P240L
2 25y7m p.P240L / p.P240L
3 25y2m p.P240L / p.P240L
4 24y2m p.P240L / p.P240L
5 17y3m p.P240L / p.R2029W
6 14y1m p.E2438K / p.N3044
7 13y3m p.P240L / p.R2029W
8 13y2m p.D1626A / p.L2223
9 13y1m p.P240L / p.P240L
10 11y8m p.P240L / p.P240L
11 11y4m p.E2438K / p.N3044
12 11y2m p.D645G / p.E956K
13 9y7m p.P240L / p.E956K
14 9y2m p.Q1716P / p.E2438K
15 8y5m p.P240L / p.E956K
16 7y3m p.P240L / p.E956K
17 7y0m p.P240L / p.P240L
18 6y4m p.P346S / p.Q1716P
20 5y9m p.P240L / c.6712 + 1
21 3y10m p.P240L / c.6712 + 1
*1Cases were shown in the order of their ages at the latest examination.
*2Genotypes written by bold word indicate truncating mutations.
*3Motor milestones: Head control < 4 months, Walking alone < 14 months.
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with CDH23 mutations [12,14,16], in addition to exclud-
ing patients with GJB2 and mitochondrial m.1555A > G
and m.3243A > G mutations. The present results indicate
that CDH23 mutations should be considered as candi-
date causes of hearing loss when patients present with
clinical features similar to the selection criteria used in
this study, which are relatively common among individ-
uals with early childhood hearing loss.
A strategy for clinical genetic diagnosis should con-
sider sensitivity, specificity, and cost. The specificity of
Sanger sequencing is known to be extremely high, but
the cost of analyzing CDH23 by Sanger sequencing is
also extremely high. The present study revealed that its
sensitivity for CHD23 was 18.1% at best. Considering
these data and recent advances in genetic technologies,
Sanger sequencing of CDH23 is not likely to be the most
practical clinical test currently available. Recently, we
and others have developed genetic tests using next-
generation sequencing (NGS) for non-syndromic hearing
loss [31-34]. The NGS-based tests can examine almost
all known deafness genes simultaneously at a cost
similar to that for Sanger sequencing of CDH23 [35,36].CDH23 mutations
Vision Fundoscopy Motor milestones*3
Normal Not done Normal
Normal Not done Normal
Normal Not done Normal
Normal Not done Normal
Normal Normal Normal
Tfs Normal Not done Normal
Myopia Normal Normal
Wfs Normal Not done Normal
Normal Not done Normal
Normal Not done Normal
Tfs Normal Not done Normal
Normal Not done Normal
Myopia Normal Normal
Normal Not done Normal
Normal Not done Normal
Normal Not done Normal
Normal Not done Normal
Normal Not done Normal
G > A Normal Not done Normal
G > A Hyperopia Normal Normal
Figure 3 Comparison of hearing levels between individuals homozygous for p.P240L and those with other homozygous mutations. A: Overlapping
audiograms of subjects with homozygous p.P240L mutations. B: Overlapping audiograms of the subjects with non-p.P240L homozygous mutations.
The subjects with homozygous p.P240L mutations tended to have more severe hearing loss at lower frequencies.
Figure 4 Comparison of hearing levels between patients with truncating and missense mutations and those with biallelic missense mutations.
A: Overlapping audiogram of subjects with truncating and missense mutations. B: Overlapping audiograms of the subjects with biallelic missense
mutations. The patterns of the audiograms were similar.
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in a limited number of institutes, but these tests will be-
come more widely available in the near future. Because
the clinical features of CDH23 mutation, i.e., congenital
sporadic or recessively inherited high-frequency hearing
loss, are relatively common and associated with muta-
tions in many deafness genes, genetic tests using NGS
would be appropriate for patients presenting with these
clinical features.
Progression is reported as an important clinical feature
of hearing loss caused by CDH23 mutations [14,16]. In
our study, progression of hearing level loss was only
noted in 10 of 21 subjects who had biallelic mutations.
In the 11 subjects who did not display obvious progres-
sive hearing loss, most were less than 5 years old at the
time of this study. In general, it is difficult to demon-
strate the progression of hearing loss in early childhood;
the observation times for younger patients are shorter
and the evaluation is performed using different audio-
logical tests depending on the developmental stages. The
results, therefore, tend to be unstable compared with
those for adults. We believe these difficulties in proving
the progression of hearing loss in early childhood ex-
plain why the ratio of progressive hearing loss in the
present study was lower than that reported previously
[14,16], and the ratio of hearing loss progression may be
higher in a follow-up study.
This study identified truncating mutations of CDH23
in combination with heterozygous missense alleles in a
Japanese population of patients with non-syndromic
deafness. In general, individuals with USH1D mostly
carry a truncated CDH23 protein because of nonsense,
frameshift, or splice-site mutations, whereas those with
DFNB12 usually carry missense mutations [7,10,13].
However, USH1D caused by missense mutations has also
been reported [37]. In addition, it has been reported that
the DFNB12 allele is phenotypically dominant to an
USH1D allele [29]. The onset of visual impairment
caused by retinitis pigmentosa accompanied by USH1D
generally occurs during adolescence [9]. In this study,
the ages of patients with monoallelic truncating muta-
tions were 3–14 years, and none of these patients had
biallelic truncating mutations. Therefore, at present we
cannot determine whether these patients have DNFB12
or USH1D, although all clinical data are compatible with
DFNB12 but not with USH1D. However, the detection
of a mild visual phenotype requires patients to be
followed with ophthalmoscopy and at least one electro-
retinography. This will provide more precise genotype-
phenotype correlations.
Conclusions
Our results revealed that CDH23 mutations are highly
prevalent in patients with congenital high-frequencysporadic or recessively inherited hearing loss and that
the mutation spectrum was diverse, indicating that pa-
tients with these clinical features would merit genetic
analysis.
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